Identification and study of new NF‐κB‐inducing kinase ligands derived from the imidazolone scaffold
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.202400614 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Francisco Maqueda-Zelaya und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Química Orgánica y Química Inorgánica, Instituto de Investigación Química "Andrés M. Del Río" (IQAR), Universidad de Alcalá (IRYCIS),…. Hauptthemen laut MEDLINE: NF-kappaB-Inducing Kinase, Imidazoles, Protein Serine-Threonine Kinases, NF-kappa B. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MICINN, Instituto de Salud Carlos III, European Union - NextGenerationEU.
Abstract (Originalsprache)
Chronic kidney disease (CKD) is a growing health concern, projected to be a major cause of death by 2040, due to an increasing risk of acute kidney injury (AKI). Systems biology‐derived data suggest that the unmet need for an orally available drug to treat AKI and improve CKD outcomes may be addressed by targeting kidney inflammation and, specifically, nuclear factor κB‐inducing kinase (NIK), a key signaling molecule that activates the noncanonical nuclear factor κB (NF‐κB) pathway. We have prepared and identified a small family of imidazolone derivatives that bind NIK and inhibit the noncanonical NF‐κB activation pathway. The introduction of heterocyclic substituents in position 2 of the imidazolone core provides compounds with affinity against human NIK. Three candidates, with best affinity profile, were tested in phenotypic experiments of noncanonical NF‐κB activation, confirming that the derivative bearing the 4‐pyridyl ring can inhibit the processing of NFκB p100 to NFkB2 p52, which is NIK‐dependent in cultured kidney tubular cells. Finally, exhaustive docking calculations combined with molecular dynamics studies led us to propose a theoretical binding mode and rationalize affinity measures, in which the aminopyridine motif is a key anchoring point to the hinge region thanks to several hydrogen bonds and the interaction of heterocyclic rings in position 2 with Ser476 and Lys482. Our result will pave the way for the development of potential drug candidates targeting NIK in the context of CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Química Orgánica y Química Inorgánica, Instituto de Investigación Química "Andrés M. Del Río" (IQAR), Universidad de Alcalá (IRYCIS), Alcalá de Henares, Madrid, Spain.
- Departamento de Nefrología e Hipertensión, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
- RICORS2040, Madrid, Spain.
- Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
Förderung
- MICINN
- Instituto de Salud Carlos III
- European Union - NextGenerationEU
- Mecanismo para la Recuperación y la Resiliencia (MRR), ERA-PerMed-JTC2022
- COST Action PERMEDIK
- COST (European Cooperation in Science and Technology)
- Comunidad de Madrid
- Universidad de Alcalá
Zitieren
APA
Maqueda-Zelaya, F., Valiño-Rivas, L., Milián, A., Gutiérrez, S., Aceña, J. L., Garcia-Marin, J., Sánchez-Niño, M. D., Vaquero, J. J., & Ortiz, A. (2025). Identification and study of new NF‐κB‐inducing kinase ligands derived from the imidazolone scaffold. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400614
Vancouver
Maqueda-Zelaya F, Valiño-Rivas L, Milián A, Gutiérrez S, Aceña JL, Garcia-Marin J, et al. Identification and study of new NF‐κB‐inducing kinase ligands derived from the imidazolone scaffold. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400614
BibTeX
@article{MaquedaZelaya2025,
author = {Maqueda-Zelaya, Francisco and Valiño-Rivas, Lara and Milián, Ana and Gutiérrez, Sara and Aceña, José Luis and Garcia-Marin, Javier and Sánchez-Niño, Mª Dolores and Vaquero, Juan J and Ortiz, Alberto},
title = {Identification and study of new NF‐κB‐inducing kinase ligands derived from the imidazolone scaffold},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.202400614}
}
EUVIMED